MEDIA RELEASE
22 September 2015
New class of antibiotic for humans that pre-clinical tests
indicate, kills superbugs;
Recce Ltd plans to list on the ASX
Highlights:
 New class of wholly synthetic antibiotic for humans that all pre-clinical tests to date,
indicate RECCE antibiotics kill all Gram-positive bacteria, Gram-negative bacteria –
and superbugs

These laboratory tests show RECCE antibiotics keep on killing after repeated use –
different from the deficiencies of many present-day antibiotics (a problem described
by World Health Organisation as “one of the greatest threats to human health today”)

RECCE antibiotics granted patents, giving manufacturing and marketing monopolies
in major pharmaceutical markets

Manufacture of RECCE antibiotics is by exceptionally economic synthesis

Recce is positioned to become in the future, a leading world-supplier of synthetic,
superbug-killing antibiotics

No other company in the world has announced comparable progress
After six years of research – an Australian scientific team led by Dr Graham Melrose announced
today that they are going forward to develop synthetic RECCE antibiotics which broadly kill bacteria,
including their superbug forms.
During the next month, the Company plans to raise A$5 million on the ASX through an initial public
offering (IPO) of 25 million shares priced at $0.20, to further develop its antibiotics that target
otherwise antibiotic-resistant bacteria.
Manufacture of the Company’s antibiotics is expected to be exceptionally economic in comparison to
present day antibiotics.
Superbugs (mutated bacteria that are antibiotic resistant) kill three quarters of a million people
worldwide on an annual basis. Moreover, the numbers are increasing.
The commercial antibiotic market is estimated at US$40 billion. A new class of antibiotic for humans
has not come onto the market for nearly 30 years.
Laboratory trials of repeated use, comparing RECCE antibiotics with Amoxicillin, a leading
commercial antibiotic, showed that RECCE antibiotics always repeatedly killed both the standard and
mutated superbug forms of all the bacteria with the same effectiveness. The commercial antibiotic
always failed the trials (against separately, Staphylococcus aureus, Escherichia coli and
Pseudomonas aeruginosa).
Dr Graham Melrose, Chairman of Recce Ltd commented, “This is the result of a completely new
approach to targeting the massive world health problem of superbugs”.
For more information, view Recce’s prospectus
Ends
For media enquiries:
Karen Oswald, Director
Marko Communications
Tel: +61 423 602 353
Email: Karen.oswald@markocommunications.com.au